Rush University Medical Center, Chicago, IL, USA.
J Clin Gastroenterol. 2009 Nov-Dec;43(10):1008-10. doi: 10.1097/MCG.0b013e31819c3945.
Oral nucleos(t)ide analogs for the treatment of hepatitis B virus (HBV) infection are well tolerated with minimal side effects. These agents do carry a Food and Drug Administration "black box" warning about the development of fatal lactic acidosis on the basis of data from the human immunodeficiency virus literature. However, no previously published cases of this lethal side effect have been reported in patients undergoing HBV treatment using the current Food and Drug Administration-approved HBV medications. We report a case of HBV reactivation after chemotherapy for leukemia, and the development of fatal lactic acidosis attributed to the use of combination oral HBV medications.
口服核苷（酸）类似物治疗乙型肝炎病毒 (HBV) 感染具有良好的耐受性，副作用极小。这些药物确实基于来自人类免疫缺陷病毒文献的数据，带有食品和药物管理局关于致命乳酸酸中毒发展的“黑框”警告。然而，在使用当前食品和药物管理局批准的 HBV 药物进行 HBV 治疗的患者中，尚未报告过这种致命副作用的先前病例。我们报告了一例白血病化疗后 HBV 再激活，并因使用联合口服 HBV 药物而导致致命乳酸酸中毒的病例。
